Pancreatic Cancer Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithm | Key Companies - Syros Pharmaceuticals (SY-5609), FibroG

As per DelveInsight, about 120+ key pharma and biotech companies are working on 150+ pipeline drugs in the Pancreatic Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Pancreatic Cancer Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Cancer Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Pancreatic Cancer Pipeline Analysis
The report provides insights into:

The report provides detailed insights into the key companies that are developing therapies in the Pancreatic Cancer Market.

The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.

It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pancreatic Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Request for Sample PDF for more detailed insights:
https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

DelveInsight's Report covers around 150+ products under different phases of clinical development like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Recent Developments in the Pancreatic Cancer Therapeutics Market
• On September 13, 2022, Syros Pharmaceutical announced that the US FDA had granted orphan drug designation (ODD) to its pancreatic cancer therapy, SY-5609. SY-5609, a highly selective and potent oral cyclin-dependent kinase 7 (CDK7) inhibitor, is currently being evaluated in combination with chemotherapy for treating patients with relapsed metastatic pancreatic cancer.

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Pancreatic Cancer Therapeutics Analysis
There are approx. 120+ key companies which are developing therapies for Pancreatic Cancer. Currently, FibroGen has its Pancreatic Cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Pancreatic Cancer Therapeutic Market include:
FibroGen, Innovent Biologics, CARsgen Therapeutics, Ascentage Pharma, NGM Biopharmaceuticals, TME Pharma AG, Lee's Pharmaceutical Limited, ImmunityBio, Inc., Rgene Corporation, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., CanBas Co. Ltd., Jiangsu HengRui Medicine Co., Ltd., Bristol-Myers Squibb, SynerGene Therapeutics, Inc., AbbVie, Silenseed Ltd, Galera Therapeutics, Inc., Helix BioPharma, Golden Biotechnology Corporation, Eli Lilly and Company, Innovent Biologics (Suzhou) Co. Ltd., Panbela Therapeutics, Inc., GlaxoSmithKline, Chia Tai Tianqing Pharmaceutical Group, Roche, Prestige Biopharma Limited, Everfront Biotech Co., Ltd., XBiotech, Inc., Incyte Corporation, Ability Pharmaceuticals SL, Lokon Pharma, HCW Biologics, Amplia Therapeutics Limited, BioLineRx, Ltd., Taiho Pharmaceutical, Sanofi, Scandion Oncology, Nelum, Celldex Therapeutics, Merus N.V., Seagen Inc., GC Cell Corporation, MetiMedi Pharmaceuticals, Lumicell, Nuvation Bio Inc., ENB Therapeutics, BioNTech SE, and many others

Pancreatic Cancer Emerging Drugs Covered in the report include:
• Pancreatic Cancer Emerging Drugs
• Pamrevlumab: FibroGen
• Niraparib: Innovent Biologics
• CT041: CARsgen Therapeutics
• APG-1387: Ascentage Pharma
• NGM120: NGM Biopharmaceuticals
And many more

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Pancreatic Cancer Current Treatment Patterns
4. Pancreatic Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Cancer Late-Stage Products (Phase-III)
7. Pancreatic Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Cancer Discontinued Products
13. Pancreatic Cancer Product Profiles
14. Pancreatic Cancer Key Companies
15. Pancreatic Cancer Key Products
16. Dormant and Discontinued Products
17. Pancreatic Cancer Unmet Needs
18. Pancreatic Cancer Future Perspectives
19. Pancreatic Cancer Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.